Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.

BMC medicine - 4 Mar 2026

Liang Jin-Hua, Wu Yi-Fan, Pan Si-Ying, Du Kai-Xin, Ji Yi-Lun, Zhu Liu-Qing, Shen Hao-Rui, Wu Jia-Zhu, Yin Hua, Li Yue, Wang Li, Li Jian-Yong, Xu Wei

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) profiling offers a noninvasive approach to monitor minimal residual disease (MRD) and clonal evolution in diffuse large B-cell lymphoma (DLBCL). METHODS: In this study, we analyzed 164 newly diagnosed DLBCL patients from the First Affiliated Hospital of Nanjing Medical University undergoing R-CHOP-like therapy. Tissue and serial plasma samples were sequenced using a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Clonal Evolution

Share to Genotype

Share to Lymphoma, Large B-Cell, Diffuse

Share to Neoplasm, Residual

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 41776568
DOI: 10.1186/s12916-026-04756-5
PMCID: PMC13067520

Genes

TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual-utility ctDNA in diffuse large B-cell lymphoma: integrated genotyping unveils minimal residual disease dynamics and subtype-specific clonal evolution.PMID 41776568Read ↗

Circulating Tumor DNA as a Biomarker of Treatment Response and Minimal Residual Disease in Diffuse Large B-Cell Lymphoma: A Literature ReviewSemantic proximity Read ↗

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.Semantic proximity Read ↗

Genetic and transcriptomic analyses of diffuse large B-cell lymphoma patients with poor outcomes within two years of diagnosisSemantic proximity Read ↗

Biological heterogeneity in diffuse large B-cell lymphomaSemantic proximity Read ↗

Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell LymphomaSemantic proximity Read ↗

Distribution and prognostic impact of LymphGen subtypes in Korean diffuse large B-cell lymphoma using clinical NGS panel.Semantic proximity Read ↗

Simplified algorithm for genetic subtyping in diffuse large B-cell lymphomaSemantic proximity Read ↗

Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.Semantic proximity Read ↗

Molecular measurable residual disease by immunoglobulin gene rearrangements on circulating tumor DNA predicts outcome in diffuse large B-cell lymphomaSemantic proximity Read ↗

High-grade B-cell lymphoma, not otherwise specified: an LLMPP studySemantic proximity Read ↗

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53-Mutated Diffuse Large B-Cell Lymphoma.Semantic proximity Read ↗

Circulating tumor DNA assisting lymphoma genetic feature profiling and identification.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.